Detalle Publicación


Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer

Autores: Vrdoljak, E.; Marschner, N.; Zielinski, C.; Gligorov, J.; Cortes, J.; Puglisi, F.; Aapro, M.; Fallowfield, L.; Fontana, A.; Inbar, M.; Kahan, Z.; Welt, A.; Levy, C.; Brain, E.; Pivot, X.; Putzu, C.; González Martín, Antonio; de Ducla, S.; Easton, V.; von Minckwitz, G.
Título de la revista: ANNALS OF ONCOLOGY
ISSN: 1569-8041
Volumen: 27
Número: 11
Páginas: 2046-2052
Fecha de publicación: 2016
In this trial, continuing bevacizumab beyond first and second progression of LR/mBC improved second-line PFS, but no improvement in longer term efficacy was observed. The second-line PFS benefit appears to be achieved without detrimentally affecting quality of life.